Literature DB >> 31955419

Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers.

C K Zigler1, K Ardalan2, A Hernandez1, A E Caliendo3, K E Magee4, M A Terry5, C M Mann1, K S Torok6.   

Abstract

BACKGROUND: Paediatric localized scleroderma (LS) can negatively impact health-related quality of life (HRQoL) by causing skin fibrosis, abnormal limb development, disfigurement, and side-effects from immunosuppressive treatment. Studies to date have rarely included qualitative data gathered directly from paediatric patients with LS.
OBJECTIVES: To assess the impact of LS on HRQoL among affected youth and their caregivers using qualitative description.
METHODS: Youth with all subtypes of LS and their caregivers were purposively sampled to participate in age-appropriate focus groups (younger children, early adolescents, adolescents). Each group started with a drawing exercise followed by in-depth discussion of topics including skin symptoms (e.g. itch, pain, tightness), functional impairment, physical appearance, family and peer relationships, and treatment burden. Focus groups were transcribed verbatim and co-coded, with adjudication of differentially applied codes. The study findings were triangulated via comparison with adult reports and published literature.
RESULTS: Eleven youth aged 9-16 years and 16 caregivers participated in three focus groups each. Major identified areas of impact included uncomfortable skin symptoms, physical functioning limitations, extracutaneous manifestations, body image, bullying and teasing, unwanted questioning from others, and treatment side-effects and burden.
CONCLUSIONS: This is the first qualitative study of HRQoL in LS to include all major LS subtypes. We identified domains of HRQoL impacted by LS, some of which replicate earlier findings and some of which were novel. As impact also changed with developmental stage, our findings support the need for ongoing, formal evaluation of HRQoL in children and adolescents with LS. What is already known about this topic? Paediatric localized scleroderma (LS) negatively impacts health-related quality of life (HRQoL) via skin fibrosis, musculoskeletal and other extracutaneous manifestations from the disease process, and side-effects of systemic immunosuppression. The full impact of LS and its treatment on HRQoL is incompletely understood, with only one published qualitative study of youth with LS, which was limited to facial involvement. There are no qualitative studies of HRQoL in other LS subtypes to date. What does this study add? This is the first qualitative evaluation of HRQoL in youth with LS inclusive of all disease subtypes. Our study confirms that LS affects HRQoL across multiple distinct domains, including uncomfortable skin sensations, impacts on body image, bullying and teasing from peers, unwanted intrusive questioning, physical limitations, extracutaneous manifestations and high treatment burden. These results indicate the need for ongoing clinical assessment of paediatric patients in these domains. What are the clinical implications of the work? These results support the need to care for patients with LS holistically by synthesizing cutaneous, musculoskeletal and extracutaneous disease assessments with multidimensional evaluation of psychosocial impact and adverse effects of treatments. The development of an LS-specific HRQoL measure would advance such efforts.
© 2020 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2020        PMID: 31955419     DOI: 10.1111/bjd.18879

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

Review 1.  Assessing Patient-Reported Outcomes in Pediatric Rheumatic Diseases: Considerations and Future Directions.

Authors:  Christina K Zigler; Rachel L Randell; Bryce B Reeve
Journal:  Rheum Dis Clin North Am       Date:  2022-02       Impact factor: 2.032

2.  The importance of development standards for anchoring vignettes: an illustrative example from pediatric localized scleroderma quality of life.

Authors:  Christina K Zigler; Heidi Jacobe; Kaveh Ardalan; Theresa M Coles; Suzane Lane; Kaila L Schollaert; Kathryn S Torok
Journal:  Qual Life Res       Date:  2020-07-11       Impact factor: 4.147

3.  The importance of children and young person involvement in scoping the need for a paediatric glucocorticoid-associated patient reported outcome measure.

Authors:  S Singhal; E M D Smith; L Roper; C E Pain
Journal:  BMC Rheumatol       Date:  2022-10-15

4.  A novel patient-reported outcome for paediatric localized scleroderma: a qualitative assessment of content validity.

Authors:  C K Zigler; K Ardalan; S Lane; K L Schollaert; K S Torok
Journal:  Br J Dermatol       Date:  2019-10-23       Impact factor: 9.302

5.  Parent Perspectives on Addressing Emotional Health for Children and Young Adults With Juvenile Myositis.

Authors:  Kaveh Ardalan; Oluwatosin Adeyemi; Dawn M Wahezi; Anne E Caliendo; Megan L Curran; Jessica Neely; Susan Kim; Colleen K Correll; Emily J Brunner; Andrea M Knight
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11-27       Impact factor: 4.794

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.